Broad Spectrum Antivirals
Preclinical
Phase I
Phase II
Phase III
Broad Spectrum Antivirals
Preclinical
Preclinical
Host-directed antiviral discovery programs
- CD45 targeted therapeutics
- Small molecule therapeutics that reduce endogenous levels of CD45, a protein tyrosine phosphatase
- Reduction in CD45 protects against many viruses including the Ebola virus
- Cathepsin inhibitors
- Small molecule therapeutics that inhibit essential cathepsins which are required by viruses such as coronaviruses and filoviruses to infect cells
- Activity as monotherapy and in combination with other antivirals
Virus-directed antivirals discovery program
- Viral glycan-targeted engineered biologics
- Bind to viral densely branched high-mannose (DBH) glycans
- Neutralize circulating virus and stop the entry of the progeny virus into cells
- Antiviral activity against a broad range of RNA viruses
- Activity as monotherapy and in combination with other antivirals